Combined SGLT2i and GLP1ra therapy reduces all-cause mortality in people with diabetes, with greater benefit in women
Nutrition, Metabolism and Cardiovascular Diseases · 2025
DOI: 10.1016/j.numecd.2025.104483 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2025. Verfasst von David Garcia-Vega und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Santiago de Compostela, Spain; Cardiology Department, Clinical Hospital of Santiago de Compostela, Spain; Centro de Investigación en Re…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Incretins. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade de Santiago de Compostela, Government of Galicia Department of Education Science Universities and Professional Training, Instituto de Investigación Sanitaria de Santiago de Compostela.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND AND AIMS: Combined therapy, sodium-glucose cotransporter 2 inhibitors (SGLT2i), and glucagon-like peptide-1 receptor agonists (GLP1ra) reduce all-cause mortality in patients with diabetes. We aimed to analyse the differential behaviour of combined therapy between women and men regarding all-cause mortality. METHODS AND RESULTS: This is a retrospective observational cohort study. Using "Big data" according to electronic medical records in the Santiago-Barbanza health area, which covers 450,000 patients. Out of 15,118 patients, 41 % were women. The median follow-up was 33 months. Women were older (71 [62-78] vs. 67 [59-75], p:
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Santiago de Compostela, Spain; Cardiology Department, Clinical Hospital of Santiago de Compostela, Spain; Centro de Investigación en Red en Enfermedades Cardiovasculares, Spain. Electronic address: david.g…
- Centro de Investigación en Red en Enfermedades Cardiovasculares, Spain; Centro de Salud de Milladoiro-Ames, Área Sanitaria de Santiago de Compostela, Spain.
- Cardiology Department, Clinical Hospital of Santiago de Compostela, Spain.
- Centro de Investigación en Red en Enfermedades Cardiovasculares, Spain; Traslational Cardiology Group, Health Research Institute of Santiago de Compostela, Spain.
- University of Santiago de Compostela, Spain; Cardiology Department, Clinical Hospital of Santiago de Compostela, Spain; Centro de Investigación en Red en Enfermedades Cardiovasculares, Spain; Traslational Cardiology Gro…
Förderung
- Universidade de Santiago de Compostela
- Government of Galicia Department of Education Science Universities and Professional Training
- Instituto de Investigación Sanitaria de Santiago de Compostela
- Fundación Instituto de Investigación Sanitaria de Santiago de Compostela
Zitieren
APA
Garcia-Vega, D., Cinza-Sanjurjo, S., Tilves-Bellas, C., Eiras, S., & González-Juanatey, J. R. (2025). Combined SGLT2i and GLP1ra therapy reduces all-cause mortality in people with diabetes, with greater benefit in women. Nutrition, Metabolism and Cardiovascular Diseases. https://doi.org/10.1016/j.numecd.2025.104483
Vancouver
Garcia-Vega D, Cinza-Sanjurjo S, Tilves-Bellas C, Eiras S, González-Juanatey JR. Combined SGLT2i and GLP1ra therapy reduces all-cause mortality in people with diabetes, with greater benefit in women. Nutrition, Metabolism and Cardiovascular Diseases. 2025. doi:10.1016/j.numecd.2025.104483
BibTeX
@article{GarciaVega2025,
author = {Garcia-Vega, David and Cinza-Sanjurjo, Sergio and Tilves-Bellas, Carlos and Eiras, Sonia and González-Juanatey, José Ramón},
title = {Combined SGLT2i and GLP1ra therapy reduces all-cause mortality in people with diabetes, with greater benefit in women},
journal = {Nutrition, Metabolism and Cardiovascular Diseases},
year = {2025},
doi = {10.1016/j.numecd.2025.104483}
}
EUVIMED